US approves twice yearly injection to prevent HIV

An injection that can prevent HIV infection for six months has been approved by the US Food and Drug Administration (FDA). Gilead’s Yeztugo (lenacapavir) becomes the longest acting form of pre-exposure prophylaxis (PrEP) against the risk of sexually acquired HIV in adults.